KEFLIN Drug Patent Profile
✉ Email this page to a colleague
When do Keflin patents expire, and when can generic versions of Keflin launch?
Keflin is a drug marketed by Lilly and is included in two NDAs.
The generic ingredient in KEFLIN is cephalothin sodium. There are seven drug master file entries for this compound. Additional details are available on the cephalothin sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for KEFLIN?
- What are the global sales for KEFLIN?
- What is Average Wholesale Price for KEFLIN?
Summary for KEFLIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 150 |
| Patent Applications: | 3,905 |
| DailyMed Link: | KEFLIN at DailyMed |
US Patents and Regulatory Information for KEFLIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | KEFLIN | cephalothin sodium | INJECTABLE;INJECTION | 050482-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | KEFLIN | cephalothin sodium | INJECTABLE;INJECTION | 050482-007 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | KEFLIN | cephalothin sodium | INJECTABLE;INJECTION | 050482-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | KEFLIN | cephalothin sodium | INJECTABLE;INJECTION | 050482-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lilly | KEFLIN IN PLASTIC CONTAINER | cephalothin sodium | INJECTABLE;INJECTION | 062549-002 | Sep 10, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
